Recent advances and developments in COVID‐19 in the context of allergic diseases

Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respirator...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and translational allergy Jg. 11; H. 7; S. e12065 - n/a
Hauptverfasser: Ding, Mei, Dong, Xiang, Sun, Yuan‐li, Sokolowska, Milena, Akdis, Mübeccel, Veen, Willem, Azkur, Ahmet Kursat, Azkur, Dilek, Akdis, Cezmi A., Gao, Ya‐dong
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England John Wiley & Sons, Inc 01.09.2021
John Wiley and Sons Inc
Wiley
Schlagworte:
Allergies
allergy
Asthma
Biomarkers
Clinical outcomes
Coronaviruses
COVID-19
Cytokines
Disease
Gene expression
Genotype & phenotype
Hay fever
Immunotherapy
Impfung
Infections
Inflammation
mechanism
Mechanismen
Medical supplies
Mortality
Pandemics
Proteins
Review
Rhinitis
Schlüsselwörter: Allergie
Severe acute respiratory syndrome coronavirus 2
Therapie
treatment
vaccination
Viral infections
Viruses
United Kingdom > UK
COVID-19
Mechanismen
treatment
Therapie
Impfung
Schlüsselwörter: Allergie
allergy
mechanism
vaccination
ISSN:2045-7022, 2045-7022
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ISSN:2045-7022
2045-7022
DOI:10.1002/clt2.12065